

# Neutralization of SARS-CoV-2 spike 69/70 deletion, E484K, vaccine-elicited sera

Nature Medicine

27, 620-621

DOI: [10.1038/s41591-021-01270-4](https://doi.org/10.1038/s41591-021-01270-4)

Citation Report

#	ARTICLE	IF	CITATIONS
1	The Genetic Variant of SARS-CoV-2: Would it matter for Controlling the Devastating Pandemic?. International Journal of Biological Sciences, 2021, 17, 1476-1485.	2.6	23
2	AutoVEM2: A flexible automated tool to analyze candidate key mutations and epidemic trends for virus. Computational and Structural Biotechnology Journal, 2021, 19, 5029-5038.	1.9	4
3	Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multi-epitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses. Emerging Microbes and Infections, 2021, 10, 1931-1946.	3.0	11
4	An overview of current COVID-19 vaccine platforms. Computational and Structural Biotechnology Journal, 2021, 19, 2508-2517.	1.9	99
7	Tri-primer-enhanced strand exchange amplification combined with rapid lateral flow fluorescence immunoassay to detect SARS-CoV-2. Analyst, The, 2021, 146, 6650-6664.	1.7	4
8	Prior aerosol infection with lineage A SARS-CoV-2 variant protects hamsters from disease, but not reinfection with B.1.351 SARS-CoV-2 variant. Emerging Microbes and Infections, 2021, 10, 1284-1292.	3.0	25
9	Live virus neutralization testing in convalescent patients and subjects vaccinated against 19A, 20B, 20I/501Y.V1 and 20H/501Y.V2 isolates of SARS-CoV-2. Emerging Microbes and Infections, 2021, 10, 1499-1502.	3.0	9
10	A rapid screening assay for L452R and T478K spike mutations in SARS-CoV-2 Delta variant using high-resolution melting analysis. Journal of Toxicological Sciences, 2021, 46, 471-476.	0.7	27
12	Making sense of spike D614G in SARS-CoV-2 transmission. Science China Life Sciences, 2021, 64, 1062-1067.	2.3	8
29	Vaccination hesitancy and the "myth" on mRNA-based vaccines in Italy in the COVID-19 era: Does urgency meet major safety criteria?. Journal of Medical Virology, 2021, 93, 4049-4053.	2.5	23
31	Escape of SARS-CoV-2 501Y.V2 from neutralization by convalescent plasma. Nature, 2021, 593, 142-146.	13.7	574
36	Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results. Frontiers in Immunology, 2021, 12, 657711.	2.2	50
38	Structure-Function Analyses of New SARS-CoV-2 Variants B.1.1.7, B.1.351 and B.1.1.28.1: Clinical, Diagnostic, Therapeutic and Public Health Implications. Viruses, 2021, 13, 439.	1.5	107
40	Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies. Nature Medicine, 2021, 27, 717-726.	15.2	838
41	The effect of SARS-CoV-2 D614G mutation on BNT162b2 vaccine-elicited neutralization. Npj Vaccines, 2021, 6, 44.	2.9	36
42	SARS-CoV-2 Episode 2? A sequel nobody wants to see. Clinical Infectious Diseases, 2021, , .	2.9	0
44	Immunity to SARS-CoV-2: Lessons Learned. Frontiers in Immunology, 2021, 12, 654165.	2.2	33
47	Target Product Profile Analysis of COVID-19 Vaccines in Phase III Clinical Trials and Beyond: An Early 2021 Perspective. Viruses, 2021, 13, 418.	1.5	51

#	ARTICLE	IF	CITATIONS
49	Perception of COVID-19 Vaccination Amongst Physicians in Colombia. <i>Vaccines</i> , 2021, 9, 287.	2.1	30
51	Neutralising antibody escape of SARS-CoV-2 spike protein: Risk assessment for antibody-based COVID-19 therapeutics and vaccines. <i>Reviews in Medical Virology</i> , 2021, 31, e2231.	3.9	128
55	Emerging SARS-CoV-2 Variants and Impact in Global Vaccination Programs against SARS-CoV-2/COVID-19. <i>Vaccines</i> , 2021, 9, 243.	2.1	217
61	Sensitivity of infectious SARS-CoV-2 B.1.1.7 and B.1.351 variants to neutralizing antibodies. <i>Nature Medicine</i> , 2021, 27, 917-924.	15.2	617
62	The effect of spike mutations on SARS-CoV-2 neutralization. <i>Cell Reports</i> , 2021, 34, 108890.	2.9	200
64	BNT162b2 mRNA COVID-19 Vaccine: First Approval. <i>Drugs</i> , 2021, 81, 495-501.	4.9	232
65	Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. <i>Nature</i> , 2021, 593, 130-135.	13.7	1,904
68	SARS-CoV-2 variants: a new challenge to convalescent serum and mRNA vaccine neutralization efficiency. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 151.	7.1	17
70	Research, Development and Application of COVID-19 Vaccines: Progress, Challenges, and Prospects. <i>Journal of Exploratory Research in Pharmacology</i> , 2021, 000, 000-000.	0.2	0
71	The variant gambit: COVID-19's next move. <i>Cell Host and Microbe</i> , 2021, 29, 508-515.	5.1	305
73	Emergence and Spread of SARS-CoV-2 Lineages B.1.1.7 and P.1 in Italy. <i>Viruses</i> , 2021, 13, 794.	1.5	32
74	Paediatric research in the times of COVID-19. <i>Pediatric Research</i> , 2021, 90, 267-271.	1.1	8
75	Obesity and its impact on COVID-19. <i>Journal of Molecular Medicine</i> , 2021, 99, 899-915.	1.7	41
76	Surveillance of SARS-CoV-2 in Frankfurt am Main from October to December 2020 Reveals High Viral Diversity Including Spike Mutation N501Y in B.1.1.70 and B.1.1.7. <i>Microorganisms</i> , 2021, 9, 748.	1.6	14
77	Impact of the N501Y substitution of SARS-CoV-2 Spike on neutralizing monoclonal antibodies targeting diverse epitopes. <i>Virology Journal</i> , 2021, 18, 87.	1.4	27
79	mRNA-Based Vaccines. <i>Vaccines</i> , 2021, 9, 390.	2.1	67
81	Adapt or perish: SARS-CoV-2 antibody escape variants defined by deletions in the Spike N-terminal Domain. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 164.	7.1	12
82	Nano-Enabled COVID-19 Vaccines: Meeting the Challenges of Durable Antibody Plus Cellular Immunity and Immune Escape. <i>ACS Nano</i> , 2021, 15, 5793-5818.	7.3	32

#	ARTICLE	IF	CITATIONS
83	Inferring the Association between the Risk of COVID-19 Case Fatality and N501Y Substitution in SARS-CoV-2. <i>Viruses</i> , 2021, 13, 638.	1.5	21
84	Immunogenicity and efficacy of one and two doses of Ad26.COVS COVID vaccine in adult and aged NHP. <i>Journal of Experimental Medicine</i> , 2021, 218, .	4.2	55
85	Effects of SARS-CoV-2 variants on vaccine efficacy and response strategies. <i>Expert Review of Vaccines</i> , 2021, 20, 365-373.	2.0	139
86	SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. <i>Cell</i> , 2021, 184, 2384-2393.e12.	13.5	848
89	A trans-complementation system for SARS-CoV-2 recapitulates authentic viral replication without virulence. <i>Cell</i> , 2021, 184, 2229-2238.e13.	13.5	51
90	The emergence of new strains of SARS-CoV-2. What does it mean for COVID-19 vaccines?. <i>Expert Review of Vaccines</i> , 2021, 20, 635-638.	2.0	66
91	Inhibitory effect of anti-HIV compounds extracted from Indian medicinal plants to retard the replication and transcription process of SARS-CoV-2: an insight from molecular docking and MD-simulation studies. <i>Network Modeling Analysis in Health Informatics and Bioinformatics</i> , 2021, 10, 32.	1.2	16
92	SARS-CoV-2 spike variants exhibit differential infectivity and neutralization resistance to convalescent or post-vaccination sera. <i>Cell Host and Microbe</i> , 2021, 29, 522-528.e2.	5.1	173
95	Comparative Perturbation-Based Modeling of the SARS-CoV-2 Spike Protein Binding with Host Receptor and Neutralizing Antibodies: Structurally Adaptable Allosteric Communication Hotspots Define Spike Sites Targeted by Global Circulating Mutations. <i>Biochemistry</i> , 2021, 60, 1459-1484.	1.2	62
96	Infection- and vaccine-induced antibody binding and neutralization of the B.1.351 SARS-CoV-2 variant. <i>Cell Host and Microbe</i> , 2021, 29, 516-521.e3.	5.1	199
98	Implications of the Novel Mutations in the SARS-CoV-2 Genome for Transmission, Disease Severity, and the Vaccine Development. <i>Frontiers in Medicine</i> , 2021, 8, 636532.	1.2	56
100	BNT162b2 mRNA COVID-19 vaccine induces antibodies of broader cross-reactivity than natural infection, but recognition of mutant viruses is up to 10-fold reduced. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2895-2998.	2.7	29
102	Structural and functional ramifications of antigenic drift in recent SARS-CoV-2 variants. <i>Science</i> , 2021, 373, 818-823.	6.0	309
108	Neutralization Heterogeneity of UK and South African Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants in BNT162b2-Vaccinated or Convalescent Coronavirus Disease 2019 (COVID-19) Healthcare Workers. <i>Clinical Infectious Diseases</i> , 2022, 74, 707-710.	2.9	10
109	Glimpses into evolutionary trajectories of SARS-CoV-2: emerging variants and potential immune evasion routes. <i>Future Microbiology</i> , 2021, 16, 455-459.	1.0	3
110	Prediction and Evolution of the Molecular Fitness of SARS-CoV-2 Variants: Introducing SpikePro. <i>Viruses</i> , 2021, 13, 935.	1.5	22
111	SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients. <i>Science Immunology</i> , 2021, 6, .	5.6	455
112	RT-qPCR Assays for Rapid Detection of the N501Y, 69-70del, K417N, and E484K SARS-CoV-2 Mutations: A Screening Strategy to Identify Variants With Clinical Impact. <i>Frontiers in Cellular and Infection Microbiology</i> , 2021, 11, 672562.	1.8	60

#	ARTICLE	IF	CITATIONS
113	SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?. <i>Advanced Drug Delivery Reviews</i> , 2021, 172, 314-338.	6.6	75
114	The Spike of Concern—The Novel Variants of SARS-CoV-2. <i>Viruses</i> , 2021, 13, 1002.	1.5	92
115	Tapping the immunological imprints to design chimeric SARS-CoV-2 vaccine for elderly population. <i>International Reviews of Immunology</i> , 2021, , 1-16.	1.5	6
116	Advances of nanomaterials—based strategies for fighting against COVID—19. <i>View</i> , 2021, 2, 20200180.	2.7	16
117	Preliminary report on severe acute respiratory syndrome coronavirus 2 (SARS—CoV—2) Spike mutation T478K. <i>Journal of Medical Virology</i> , 2021, 93, 5638-5643.	2.5	129
118	SARS-CoV-2 escaped natural immunity, raising questions about vaccines and therapies. <i>Nature Medicine</i> , 2021, 27, 759-761.	15.2	65
119	SARS—CoV—2 worldwide replication drives rapid rise and selection of mutations across the viral genome: a time—course study — potential challenge for vaccines and therapies. <i>EMBO Molecular Medicine</i> , 2021, 13, e14062.	3.3	28
122	Regulatory concepts to guide and promote the accelerated but safe clinical development and licensure of COVID—19 vaccines in Europe. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 72-82.	2.7	11
124	Sensitive Immunodetection of Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern 501Y.V2 and 501Y.V1. <i>Journal of Infectious Diseases</i> , 2021, 224, 616-619.	1.9	3
126	Response to mutation and variants of the SARS-CoV-2 gene. <i>Universa Medicina</i> , 2021, 40, 77-78.	0.1	3
127	On the road to ending the COVID-19 pandemic: Are we there yet?. <i>Virology</i> , 2021, 557, 70-85.	1.1	38
128	<sc>COVID</sc>—19: vaccination problems. <i>Environmental Microbiology</i> , 2021, 23, 2878-2890.	1.8	46
129	COVID-19 one year into the pandemic: from genetics and genomics to therapy, vaccination, and policy. <i>Human Genomics</i> , 2021, 15, 27.	1.4	39
130	BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans. <i>Nature</i> , 2021, 595, 572-577.	13.7	583
131	Use of Lateral Flow Immunoassay to Characterize SARS-CoV-2 RBD-Specific Antibodies and Their Ability to React with the UK, SA and BR P.1 Variant RBDs. <i>Diagnostics</i> , 2021, 11, 1190.	1.3	10
133	Observational study on healthcare workers protection in the angiographic suite during the SARS-CoV-2 pandemic: before and during vax era. <i>Journal of Public Health Research</i> , 2021, 10, .	0.5	1
134	Tozinameran (BNT162b2) Vaccine: The Journey from Preclinical Research to Clinical Trials and Authorization. <i>AAPS PharmSciTech</i> , 2021, 22, 172.	1.5	24
135	Humoral Immunity against SARS-CoV-2 and the Impact on COVID-19 Pathogenesis. <i>Molecules and Cells</i> , 2021, 44, 392-400.	1.0	22

#	ARTICLE	IF	CITATIONS
136	Rapid Increase of SARS-CoV-2 Variant B.1.1.7 Detected in Sewage Samples from England between October 2020 and January 2021. <i>MSystems</i> , 2021, 6, e0035321.	1.7	46
137	Comparison and Analysis of Neutralizing Antibody Levels in Serum after Inoculating with SARS-CoV-2, MERS-CoV, or SARS-CoV Vaccines in Humans. <i>Vaccines</i> , 2021, 9, 588.	2.1	12
138	Application of an integrated computational antibody engineering platform to design SARS-CoV-2 neutralizers. <i>Antibody Therapeutics</i> , 2021, 4, 109-122.	1.2	8
140	SARS-CoV-2 Portrayed against HIV: Contrary Viral Strategies in Similar Disguise. <i>Microorganisms</i> , 2021, 9, 1389.	1.6	4
141	SARS-CoV-2 variants, spike mutations and immune escape. <i>Nature Reviews Microbiology</i> , 2021, 19, 409-424.	13.6	2,650
142	Safety and Efficacy of Single-Dose Ad26.COVS.2 Vaccine against Covid-19. <i>New England Journal of Medicine</i> , 2021, 384, 2187-2201.	13.9	1,954
144	Rapid Detection of SARS-CoV-2 Variants of Concern, Including B.1.1.28/P.1, British Columbia, Canada. <i>Emerging Infectious Diseases</i> , 2021, 27, 1673-1676.	2.0	38
145	Adjusting extracellular pH to prevent entry of SARS-CoV-2 into human cells. <i>Genome</i> , 2021, 64, 595-598.	0.9	7
146	An mRNA-based vaccine candidate against SARS-CoV-2 elicits stable immuno-response with single dose. <i>Vaccine</i> , 2021, 39, 3745-3755.	1.7	9
147	SARS-CoV-2 Brazil variants in Latin America: More serious research urgently needed on public health and vaccine protection. <i>Annals of Medicine and Surgery</i> , 2021, 66, 102428.	0.5	18
149	Effect of natural mutations of SARS-CoV-2 on spike structure, conformation, and antigenicity. <i>Science</i> , 2021, 373, .	6.0	318
150	Detection of R.1 lineage severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with spike protein W152L/E484K/G769V mutations in Japan. <i>PLoS Pathogens</i> , 2021, 17, e1009619.	2.1	40
151	In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains. <i>Nature</i> , 2021, 596, 103-108.	13.7	222
152	CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral B BavPat1 and emerging B.1.351 SARS-CoV-2. <i>Nature Communications</i> , 2021, 12, 4048.	5.8	45
153	SARS-CoV-2 Variants: A Synopsis of In Vitro Efficacy Data of Convalescent Plasma, Currently Marketed Vaccines, and Monoclonal Antibodies. <i>Viruses</i> , 2021, 13, 1211.	1.5	35
155	Convalescent-Phase Sera and Vaccine-Elicited Antibodies Largely Maintain Neutralizing Titer against Global SARS-CoV-2 Variant Spikes. <i>MBio</i> , 2021, 12, e0069621.	1.8	61
156	Allosteric Cross-Talk among Spike's Receptor-Binding Domain Mutations of the SARS-CoV-2 South African Variant Triggers an Effective Hijacking of Human Cell Receptor. <i>Journal of Physical Chemistry Letters</i> , 2021, 12, 5987-5993.	2.1	33
158	BNT162b2-elicited neutralization of B.1.617 and other SARS-CoV-2 variants. <i>Nature</i> , 2021, 596, 273-275.	13.7	318

#	ARTICLE	IF	CITATIONS
159	SARS-CoV-2 Entry: At the Crossroads of CD147 and ACE2. <i>Cells</i> , 2021, 10, 1434.	1.8	60
160	SARS-CoV-2 mutations in Brazil: from genomics to putative clinical conditions. <i>Scientific Reports</i> , 2021, 11, 11998.	1.6	17
161	SARS-CoV-2 spillover transmission due to recombination event. <i>Gene Reports</i> , 2021, 23, 101045.	0.4	11
162	The Antigenicity of Epidemic SARS-CoV-2 Variants in the United Kingdom. <i>Frontiers in Immunology</i> , 2021, 12, 687869.	2.2	23
165	Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. <i>Nature Medicine</i> , 2021, 27, 1379-1384.	15.2	296
168	Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host. <i>Virus Evolution</i> , 2021, 7, veab061.	2.2	12
169	Fast-spreading SARS-CoV-2 variants: challenges to and new design strategies of COVID-19 vaccines. <i>Signal Transduction and Targeted Therapy</i> , 2021, 6, 226.	7.1	103
170	Fncas9-based CRISPR diagnostic for rapid and accurate detection of major SARS-CoV-2 variants on a paper strip. <i>ELife</i> , 2021, 10, .	2.8	53
171	Humoral and Cellular Immune Responses Against Severe Acute Respiratory Syndrome Coronavirus 2 Variants and Human Coronaviruses After Single BNT162b2 Vaccination. <i>Clinical Infectious Diseases</i> , 2021, 73, 2000-2008.	2.9	30
172	Transmission, infectivity, and neutralization of a spike L452R SARS-CoV-2 variant. <i>Cell</i> , 2021, 184, 3426-3437.e8.	13.5	424
174	COVID-19: 1/4D, N, N, D, NEDμD°D»NCE1/2D3/4NÑ,ÑCE. <i>Biochemistry</i> , 2021, 86, 964-984.	0.0	0
175	SARS-CoV-2 Vaccines Based on the Spike Glycoprotein and Implications of New Viral Variants. <i>Frontiers in Immunology</i> , 2021, 12, 701501.	2.2	157
176	SARS-CoV-2 immune evasion by the B.1.427/B.1.429 variant of concern. <i>Science</i> , 2021, 373, 648-654.	6.0	385
179	Molecular definition of severe acute respiratory syndrome coronavirus 2 receptorâ€binding domain mutations: Receptor affinity versus neutralization of receptor interaction. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 143-149.	2.7	26
180	Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC:) Tj ETQq0 0 0 rgBT/Overlock 10 Tf 50	2.1	94
181	Potency of BNT162b2 and mRNAâ€1273 vaccineâ€induced neutralizing antibodies against severe acute respiratory syndromeâ€CoVâ€2 variants of concern: A systematic review of in vitro studies. <i>Reviews in Medical Virology</i> , 2022, 32, e2277.	3.9	57
182	SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination. <i>Cell Reports</i> , 2021, 36, 109415.	2.9	206
183	Multiplex SARS-CoV-2 Genotyping Reverse Transcriptase PCR for Population-Level Variant Screening and Epidemiologic Surveillance. <i>Journal of Clinical Microbiology</i> , 2021, 59, e0085921.	1.8	82

#	ARTICLE	IF	CITATIONS
184	SARS-CoV-2 Mutations and their Viral Variants. Cytokine and Growth Factor Reviews, 2022, 63, 10-22.	3.2	113
185	The impact of spike mutated variants of SARS-CoV2 [Alpha, Beta, Gamma, Delta, and Lambda] on the efficacy of subunit recombinant vaccines. Brazilian Journal of Infectious Diseases, 2021, 25, 101606.	0.3	94
187	Mutants of human ACE2 differentially promote SARS-CoV and SARS-CoV-2 spike mediated infection. PLoS Pathogens, 2021, 17, e1009715.	2.1	24
188	Navigating post-vaccine COVID-19 futures in the health and economic context. Lancet Infectious Diseases, The, 2021, 21, 893-894.	4.6	3
190	Modification of the Spike Protein for Vaccines against Enveloped RNA Viruses. Molecular Biology, 2021, 55, 538-547.	0.4	2
192	COVID-19: Myths and Reality. Biochemistry (Moscow), 2021, 86, 800-817.	0.7	10
195	COVID-19: Unmasking Emerging SARS-CoV-2 Variants, Vaccines and Therapeutic Strategies. Biomolecules, 2021, 11, 993.	1.8	136
196	An Observational Cohort Study on the Incidence of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection and B.1.1.7 Variant Infection in Healthcare Workers by Antibody and Vaccination Status. Clinical Infectious Diseases, 2022, 74, 1208-1219.	2.9	64
201	Clinical and virological course of patients with coronavirus disease 2019 in Jiangsu province, China: a retrospective, multi-center cohort study. Virology Journal, 2021, 18, 147.	1.4	2
203	Original Hosts, Clinical Features, Transmission Routes, and Vaccine Development for Coronavirus Disease (COVID-19). Frontiers in Medicine, 2021, 8, 702066.	1.2	14
204	Possible Targets of Pan-Coronavirus Antiviral Strategies for Emerging or Re-Emerging Coronaviruses. Microorganisms, 2021, 9, 1479.	1.6	10
205	Ultrapotent miniproteins targeting the SARS-CoV-2 receptor-binding domain protect against infection and disease. Cell Host and Microbe, 2021, 29, 1151-1161.e5.	5.1	36
208	Rapid evolution of the COVID-19 pandemic calls for a unified public health response. BioScience Trends, 2021, 15, 196-200.	1.1	5
209	Epigallocatechin gallate from green tea effectively blocks infection of SARS-CoV-2 and new variants by inhibiting spike binding to ACE2 receptor. Cell and Bioscience, 2021, 11, 168.	2.1	69
210	BNT162b2 SARS-CoV-2 Vaccination Elicits High Titers of Neutralizing Antibodies to Both B.1 and P.1 Variants in Previously Infected and Uninfected Subjects. Life, 2021, 11, 896.	1.1	2
211	Antibody Responses to Natural SARS-CoV-2 Infection or after COVID-19 Vaccination. Vaccines, 2021, 9, 910.	2.1	50
212	B.1.526 SARS-CoV-2 Variants Identified in New York City are Neutralized by Vaccine-Elicited and Therapeutic Monoclonal Antibodies. MBio, 2021, 12, e0138621.	1.8	52
214	Assessment of the potentially decreased neutralizing activities of intravenous immunoglobulin against future coronavirus variants. Transfusion, 2021, 61, 2514-2515.	0.8	1



#	ARTICLE	IF	CITATIONS
215	Probing the Increased Virulence of Severe Acute Respiratory Syndrome Coronavirus 2 B.1.617 (Indian) Tj ETQq0 0 0 rgBT /Overlock 10 T	0.2	3
216	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, .	2.3	33
217	One year into the pandemic: Short-term evolution of SARS-CoV-2 and emergence of new lineages. Infection, Genetics and Evolution, 2021, 92, 104869.	1.0	49
218	Computationally Designed ACE2 Decoy Receptor Binds SARS-CoV-2 Spike (S) Protein with Tight Nanomolar Affinity. Journal of Chemical Information and Modeling, 2021, 61, 4656-4669.	2.5	24
219	SARS-CoV-2 vaccines â€” the biggest medical research project of the 21st century. Current Opinion in Virology, 2021, 49, 52-57.	2.6	12
220	The impact of high-resolution structural data on stemming the COVID-19 pandemic. Current Opinion in Virology, 2021, 49, 127-138.	2.6	2
221	Therapeutic targets and interventional strategies in COVID-19: mechanisms and clinical studies. Signal Transduction and Targeted Therapy, 2021, 6, 317.	7.1	68
222	Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nature Reviews Immunology, 2021, 21, 626-636.	10.6	777
223	An Analysis Based on Molecular Docking and Molecular Dynamics Simulation Study of Bromelain as Anti-SARS-CoV-2 Variants. Frontiers in Pharmacology, 2021, 12, 717757.	1.6	28
224	Evolutionary trajectory of SARS-CoV-2 and emerging variants. Virology Journal, 2021, 18, 166.	1.4	105
225	SARS-CoV-2 Infection: New Molecular, Phylogenetic, and Pathogenetic Insights. Efficacy of Current Vaccines and the Potential Risk of Variants. Viruses, 2021, 13, 1687.	1.5	57
226	The rapid adaptation of SARS-CoV-2â€”rise of the variants: transmission and resistance. Journal of Microbiology, 2021, 59, 807-818.	1.3	18
228	An update comprehensive review on the status of COVID-19: vaccines, drugs, variants and neurological symptoms. Turkish Journal of Biology, 2021, 45, 342-357.	2.1	3
229	Therapeutic effect of CT-P59 against SARS-CoV-2 South African variant. Biochemical and Biophysical Research Communications, 2021, 566, 135-140.	1.0	46
230	Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum. Nature Communications, 2021, 12, 5135.	5.8	107
231	Using Twitter for sentiment analysis towards AstraZeneca/Oxford, Pfizer/BioNTech and Moderna COVID-19 vaccines. Postgraduate Medical Journal, 2022, 98, 544-550.	0.9	80
232	Cross-Neutralizing Activity Against SARS-CoV-2 Variants in COVID-19 Patients: Comparison of 4 Waves of the Pandemic in Japan. Open Forum Infectious Diseases, 2021, 8, ofab430.	0.4	18
233	Comparative kinetics of SARS-CoV-2 anti-spike protein RBD IgGs and neutralizing antibodies in convalescent and naïve recipients of the BNT162b2 mRNA vaccine versus COVID-19 patients. BMC Medicine, 2021, 19, 208.	2.3	52

#	ARTICLE	IF	CITATIONS
234	The New Variants of Corona-Virus Mutations: An Understanding to Their Infectivity, Immunological Tolerance and Vaccine Efficacy. <i>Nano LIFE</i> , 2021, 11, 2130010.	0.6	1
235	Signatures in SARS-CoV-2 spike protein conferring escape to neutralizing antibodies. <i>PLoS Pathogens</i> , 2021, 17, e1009772.	2.1	74
237	A pair of noncompeting neutralizing human monoclonal antibodies protecting from disease in a SARS-CoV-2 infection model. <i>European Journal of Immunology</i> , 2022, 52, 770-783.	1.6	24
238	The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. <i>EBioMedicine</i> , 2021, 71, 103544.	2.7	38
240	Fast SARS-CoV-2 Variant Detection Using Snapback Primer High-Resolution Melting. <i>Diagnostics</i> , 2021, 11, 1788.	1.3	8
241	In vitro data suggest that Indian delta variant B.1.617 of SARS-CoV-2 escapes neutralization by both receptor affinity and immune evasion. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 111-117.	2.7	69
242	Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination. <i>Cell Reports Medicine</i> , 2021, 2, 100405.	3.3	110
243	Genetic drift in the genome of SARS-CoV-2 and its global health concern. <i>Journal of Medical Virology</i> , 2022, 94, 88-98.	2.5	17
244	An ultrapotent pan- $\beta$ -coronavirus lineage B ( $\beta$ -CoV-B) neutralizing antibody locks the receptor-binding domain in closed conformation by targeting its conserved epitope. <i>Protein and Cell</i> , 2022, 13, 655-675.	4.8	25
245	From influenza to COVID-19: Lipid nanoparticle mRNA vaccines at the frontiers of infectious diseases. <i>Acta Biomaterialia</i> , 2021, 131, 16-40.	4.1	140
246	Potent neutralization of SARS-CoV-2 variants of concern by an antibody with an uncommon genetic signature and structural mode of spike recognition. <i>Cell Reports</i> , 2021, 37, 109784.	2.9	20
248	Neglected roles of IgG Fc-binding protein secreted from airway mucin-producing cells in protecting against SARS-CoV-2 infection. <i>Innate Immunity</i> , 2021, 27, 423-436.	1.1	6
249	Cheap and Commonplace: Making the Case for BCG and $\gamma\delta$ T Cells in COVID-19. <i>Frontiers in Immunology</i> , 2021, 12, 743924.	2.2	4
250	Single base mutations in the nucleocapsid gene of SARS-CoV-2 affects amplification efficiency of sequence variants and may lead to assay failure. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100037.	0.4	6
251	Synthetic proteins for COVID-19 diagnostics. <i>Peptides</i> , 2021, 143, 170583.	1.2	5
252	Exploring the Interaction between E484K and N501Y Substitutions of SARS-CoV-2 in Shaping the Transmission Advantage of COVID-19 in Brazil: A Modeling Study. <i>American Journal of Tropical Medicine and Hygiene</i> , 2021, 105, 1247-1254.	0.6	5
253	Rapid and Quantitative Detection of Human Antibodies against the 2019 Novel Coronavirus SARS-CoV-2 and Its Variants as a Result of Vaccination and Infection. <i>Microbiology Spectrum</i> , 2021, 9, e0089021.	1.2	2
254	E484K as an innovative phylogenetic event for viral evolution: Genomic analysis of the E484K spike mutation in SARS-CoV-2 lineages from Brazil. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104941.	1.0	58

#	ARTICLE	IF	CITATIONS
255	Understanding the molecular interaction of SARS-CoV-2 spike mutants with ACE2 (angiotensin) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 74	2.0	19
257	Shooting at a Moving Target—Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development. <i>Vaccines</i> , 2021, 9, 1052.	2.1	22
258	SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1. <i>Vaccine</i> , 2021, 39, 5769-5779.	1.7	23
259	The biological and clinical significance of emerging SARS-CoV-2 variants. <i>Nature Reviews Genetics</i> , 2021, 22, 757-773.	7.7	778
260	Emerging SARS-CoV-2 Variants of Concern (VOCs): An Impending Global Crisis. <i>Biomedicines</i> , 2021, 9, 1303.	1.4	87
261	A bioluminescent and homogeneous SARS-CoV-2 spike RBD and hACE2 interaction assay for antiviral screening and monitoring patient neutralizing antibody levels. <i>Scientific Reports</i> , 2021, 11, 18428.	1.6	10
262	Impact of mutations in SARS-COV-2 spike on viral infectivity and antigenicity. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	16
263	REGEN-COV Antibody Combination and Outcomes in Outpatients with Covid-19. <i>New England Journal of Medicine</i> , 2021, 385, e81.	13.9	487
264	Memory B cell repertoire for recognition of evolving SARS-CoV-2 spike. <i>Cell</i> , 2021, 184, 4969-4980.e15.	13.5	94
265	Comparison of an inactivated Covid19 vaccine-induced antibody response with concurrent natural Covid19 infection. <i>International Journal of Infectious Diseases</i> , 2021, 113, 58-64.	1.5	24
266	RBD-homodimer, a COVID-19 subunit vaccine candidate, elicits immunogenicity and protection in rodents and nonhuman primates. <i>Cell Discovery</i> , 2021, 7, 82.	3.1	22
267	Application of Artificial Intelligence in COVID-19 Diagnosis and Therapeutics. <i>Journal of Personalized Medicine</i> , 2021, 11, 886.	1.1	17
268	Recent progress on the mutations of SARS-CoV-2 spike protein and suggestions for prevention and controlling of the pandemic. <i>Infection, Genetics and Evolution</i> , 2021, 93, 104971.	1.0	19
269	Severe Acute Respiratory Syndrome Coronavirus-2 Infection and Autoimmunity 1 Year Later: The Era of Vaccines. <i>Frontiers in Immunology</i> , 2021, 12, 708848.	2.2	7
270	mRNA vaccination of naive and COVID-19-recovered individuals elicits potent memory B cells that recognize SARS-CoV-2 variants. <i>Immunity</i> , 2021, 54, 2893-2907.e5.	6.6	107
271	COVID-19 vaccine uptake among healthcare workers in the fourth country to authorize BNT162b2 during the first month of rollout. <i>Vaccine</i> , 2021, 39, 5762-5768.	1.7	49
272	Emergence of the Delta Plus variant of SARS-CoV-2 in Iran. <i>Gene Reports</i> , 2021, 25, 101341.	0.4	12
273	Neutralization of alpha, gamma, and D614G SARS-CoV-2 variants by CoronaVac vaccine-induced antibodies. <i>Journal of Medical Virology</i> , 2022, 94, 399-403.	2.5	23

#	ARTICLE	IF	CITATIONS
274	Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. <i>New England Journal of Medicine</i> , 2021, 385, 1761-1773.	13.9	1,090
275	A tetrameric ACE2 protein broadly neutralizes SARS-CoV-2 spike variants of concern with elevated potency. <i>Antiviral Research</i> , 2021, 194, 105147.	1.9	11
276	Cross-neutralization of SARS-CoV-2 B.1.1.7 and P.1 variants in vaccinated, convalescent and P.1 infected. <i>Journal of Infection</i> , 2021, 83, 467-472.	1.7	28
277	Deamidation drives molecular aging of the SARS-CoV-2 spike protein receptor-binding motif. <i>Journal of Biological Chemistry</i> , 2021, 297, 101175.	1.6	3
278	Characterization of the emerging B.1.621 variant of interest of SARS-CoV-2. <i>Infection, Genetics and Evolution</i> , 2021, 95, 105038.	1.0	110
279	Wastewater SARS-CoV-2 monitoring as a community-level COVID-19 trend tracker and variants in Ohio, United States. <i>Science of the Total Environment</i> , 2021, 801, 149757.	3.9	107
280	Highly sensitive and ultra-rapid antigen-based detection of SARS-CoV-2 using nanomechanical sensor platform. <i>Biosensors and Bioelectronics</i> , 2022, 195, 113647.	5.3	34
281	Structure of SARS-CoV-2 Spike Glycoprotein for Therapeutic and Preventive Target. <i>Immune Network</i> , 2021, 21, e8.	1.6	3
282	Introduction of SARS-CoV-2 variant of concern 20h/501Y.V2 (B.1.351) from Malawi to Italy. <i>Emerging Microbes and Infections</i> , 2021, 10, 710-712.	3.0	7
283	Potent RBD-specific neutralizing rabbit monoclonal antibodies recognize emerging SARS-CoV-2 variants elicited by DNA prime-protein boost vaccination. <i>Emerging Microbes and Infections</i> , 2021, 10, 1390-1403.	3.0	16
285	Microscopic interactions between ivermectin and key human and viral proteins involved in SARS-CoV-2 infection. <i>Physical Chemistry Chemical Physics</i> , 2021, 23, 22957-22971.	1.3	11
286	SARS-CoV-2 Variants of Concern. <i>Yonsei Medical Journal</i> , 2021, 62, 961.	0.9	183
287	A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies. <i>International Journal of Immunopathology and Pharmacology</i> , 2021, 35, 205873842110501.	1.0	26
288	INO-4800 DNA vaccine induces neutralizing antibodies and T cell activity against global SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2021, 6, 121.	2.9	36
289	Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera. <i>IScience</i> , 2021, 24, 103341.	1.9	47
290	Resistance of SARS-CoV-2 variants to neutralization by convalescent plasma from early COVID-19 outbreak in Singapore. <i>Npj Vaccines</i> , 2021, 6, 125.	2.9	17
291	Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review. <i>Clinical Microbiology and Infection</i> , 2022, 28, 202-221.	2.8	569
292	Molecular Analysis and Genome Sequencing of SARS-Cov-2 during Second Wave 2021 Revealed Variant Diversity in India. <i>Journal of Pure and Applied Microbiology</i> , 0, , .	0.3	1

#	ARTICLE	IF	CITATIONS
293	Vaccination against COVID-19 for hematologic patients: A review of clinical guidelines. <i>Gematologiya i Transfuziologiya</i> , 2021, 66, 458-470.	0.1	1
294	Impact of circulating SARS-CoV-2 variants on mRNA vaccine-induced immunity. <i>Nature</i> , 2021, 600, 523-529.	13.7	194
295	Imaging and visualizing SARS-CoV-2 in a new era for structural biology. <i>Interface Focus</i> , 2021, 11, 20210019.	1.5	5
296	Longitudinal Humoral Responses after COVID-19 Vaccination in Peritoneal and Hemodialysis Patients over Twelve Weeks. <i>Vaccines</i> , 2021, 9, 1130.	2.1	36
297	ChAdOx1 nCoV-19 (AZD1222) protects Syrian hamsters against SARS-CoV-2 B.1.351 and B.1.1.7. <i>Nature Communications</i> , 2021, 12, 5868.	5.8	52
298	Single domain shark VNAR antibodies neutralize SARS-CoV-2 infection in vitro. <i>FASEB Journal</i> , 2021, 35, e21970.	0.2	22
299	Real-time quantification of the transmission advantage associated with a single mutation in pathogen genomes: a case study on the D614G substitution of SARS-CoV-2. <i>BMC Infectious Diseases</i> , 2021, 21, 1039.	1.3	2
300	COVID-19 Vaccine Platforms: Challenges and Safety Contemplations. <i>Vaccines</i> , 2021, 9, 1196.	2.1	15
301	A Newcastle disease virus expressing a stabilized spike protein of SARS-CoV-2 induces protective immune responses. <i>Nature Communications</i> , 2021, 12, 6197.	5.8	61
302	Engineering Extracellular Vesicles Enriched with Palmitoylated ACE2 as COVID-19 Therapy. <i>Advanced Materials</i> , 2021, 33, e2103471.	11.1	60
303	Triple jeopardy in ageing: COVID-19, co-morbidities and inflamm-ageing. <i>Ageing Research Reviews</i> , 2022, 73, 101494.	5.0	11
304	Comparative characteristics of COVID-19 vaccines used for mass immunisation. <i>BIOpreparations Prevention Diagnosis Treatment</i> , 2021, 21, 158-166.	0.2	6
305	Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines. <i>Viruses</i> , 2021, 13, 2127.	1.5	6
307	GRAd-COV2, a gorilla adenovirus-based candidate vaccine against COVID-19, is safe and immunogenic in younger and older adults. <i>Science Translational Medicine</i> , 2022, 14, eabj1996.	5.8	18
308	Isolation of a panel of ultra-potent human antibodies neutralizing SARS-CoV-2 and viral variants of concern. <i>Cell Discovery</i> , 2021, 7, 96.	3.1	21
311	Mutational profile confers increased stability of SARS-CoV-2 spike protein in Brazilian isolates. <i>Journal of Biomolecular Structure and Dynamics</i> , 2022, 40, 13184-13189.	2.0	3
312	A practical approach to SARS-CoV-2 testing in a pre and post-vaccination era. <i>Journal of Clinical Virology Plus</i> , 2021, 1, 100044.	0.4	2
313	Complete protection by a single-dose skin patch-delivered SARS-CoV-2 spike vaccine. <i>Science Advances</i> , 2021, 7, eabj8065.	4.7	31

#	ARTICLE	IF	CITATIONS
314	Neutralizing Antibodies to SARS-CoV-2 Selected from a Human Antibody Library Constructed Decades Ago. <i>Advanced Science</i> , 2022, 9, e2102181.	5.6	14
315	SARS-CoV-2 surveillance in Italy through phylogenomic inferences based on Hamming distances derived from pan-SNPs, -MNP and -InDels. <i>BMC Genomics</i> , 2021, 22, 782.	1.2	12
316	Survey of SARS-CoV-2 genetic diversity in two major Brazilian cities using a fast and affordable Sanger sequencing strategy. <i>Genomics</i> , 2021, 113, 4109-4115.	1.3	9
317	Immuno-informatics analysis predicts B and T cell consensus epitopes for designing peptide vaccine against SARS-CoV-2 with 99.82% global population coverage. <i>Briefings in Bioinformatics</i> , 2022, 23, .	3.2	5
318	Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine. <i>Frontiers in Immunology</i> , 2021, 12, 747830.	2.2	69
319	A review of epidemiology, clinical features and disease course, transmission dynamics, and neutralization efficacy of SARS-CoV-2 variants. <i>Egyptian Journal of Bronchology</i> , 2021, 15, .	0.3	4
320	SARS-CoV-2 variants and effectiveness of vaccines: a review of current evidence. <i>Epidemiology and Infection</i> , 2021, 149, 1-24.	1.0	43
321	Evaluating the Neutralizing Ability of a CpG-Adjuvanted S-2P Subunit Vaccine Against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Variants of Concern. <i>Clinical Infectious Diseases</i> , 2022, 74, 1899-1905.	2.9	15
322	SARS-CoV-2 mRNA vaccine BNT162b2 triggers a consistent cross-variant humoral and cellular response. <i>Emerging Microbes and Infections</i> , 2021, 10, 2235-2243.	3.0	31
323	Antibody neutralization to SARS-CoV-2 and variants after 1 year in Wuhan, China. <i>Innovation(China)</i> , 2022, 3, 100181.	5.2	8
324	Coronavirus Disease Update on Epidemiology, Virology, and Prevention. <i>Compendium of Continuing Education in Dentistry (Jamesburg, N J: 1995)</i> , 2021, 42, 280-289.	0.1	0
325	The Importance of RNA-Based Vaccines in the Fight against COVID-19: An Overview. <i>Vaccines</i> , 2021, 9, 1345.	2.1	22
326	National responses to covid-19: drivers, complexities, and uncertainties in the first year of the pandemic. <i>BMJ, The</i> , 2021, 375, e068954.	3.0	11
327	The N501Y spike substitution enhances SARS-CoV-2 infection and transmission. <i>Nature</i> , 2022, 602, 294-299.	13.7	364
328	Cross-reactive antibodies after SARS-CoV-2 infection and vaccination. <i>ELife</i> , 2021, 10, .	2.8	63
329	Comparing the clinical efficacy of COVID-19 vaccines: a systematic review and network meta-analysis. <i>Scientific Reports</i> , 2021, 11, 22777.	1.6	159
330	Immune response against SARS-CoV-2 variants: the role of neutralization assays. <i>Npj Vaccines</i> , 2021, 6, 142.	2.9	26
331	Mucosal vaccination induces protection against SARS-CoV-2 in the absence of detectable neutralizing antibodies. <i>Npj Vaccines</i> , 2021, 6, 139.	2.9	8

#	ARTICLE	IF	CITATIONS
332	Counting on COVID-19 Vaccine: Insights into the Current Strategies, Progress and Future Challenges. <i>Biomedicines</i> , 2021, 9, 1740.	1.4	16
333	Highly Neutralizing COVID-19 Convalescent Plasmas Potently Block SARS-CoV-2 Replication and Pneumonia in Syrian Hamsters. <i>Journal of Virology</i> , 2022, 96, JVI0155121.	1.5	18
334	Mutations of SARS-CoV-2 spike protein: Implications on immune evasion and vaccine-induced immunity. <i>Seminars in Immunology</i> , 2021, 55, 101533.	2.7	72
335	Phylogenetic and full-length genome mutation analysis of SARS-CoV-2 in Indonesia prior to COVID-19 vaccination program in 2021. <i>Bulletin of the National Research Centre</i> , 2021, 45, 200.	0.7	8
337	Antibody cocktail effective against variants of SARS-CoV-2. <i>Journal of Biomedical Science</i> , 2021, 28, 80.	2.6	17
338	Covid-19 vaccines and variants of concern: A review. <i>Reviews in Medical Virology</i> , 2022, 32, e2313.	3.9	201
339	Emerging Mutations Potentially Related to SARS-CoV-2 Immune Escape: The Case of a Long-Term Patient. <i>Life</i> , 2021, 11, 1259.	1.1	2
340	COVID-19 reinfection: the role of natural immunity, vaccines, and variants. <i>Journal of Community Hospital Internal Medicine Perspectives</i> , 2021, 11, 733-739.	0.4	22
341	CRISPR-Cas12a-Based Detection for the Major SARS-CoV-2 Variants of Concern. <i>Microbiology Spectrum</i> , 2021, 9, e0101721.	1.2	40
342	A year living with SARS-CoV-2: an epidemiological overview of viral lineage circulation by whole-genome sequencing in Barcelona city (Catalonia, Spain). <i>Emerging Microbes and Infections</i> , 2022, 11, 172-181.	3.0	17
343	A review of epidemiology and public health control measures of COVID-19 variants in Hong Kong, December 2020 to June 2021. <i>IJID Regions</i> , 2022, 2, 16-24.	0.5	8
344	Correlates of neutralizing/SARS-CoV-2-S1-binding antibody response with adverse effects and immune kinetics in BNT162b2-vaccinated individuals. <i>Scientific Reports</i> , 2021, 11, 22848.	1.6	57
345	Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. <i>Microbiology Spectrum</i> , 2021, 9, e0056121.	1.2	15
346	SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera. <i>Science</i> , 2021, 24, 103467.	1.9	26
347	The intestinal microbiota and improving the efficacy of COVID-19 vaccinations. <i>Journal of Functional Foods</i> , 2021, 87, 104850.	1.6	23
348	Evolutionary Dynamics of Indels in SARS-CoV-2 Spike Glycoprotein. <i>Evolutionary Bioinformatics</i> , 2021, 17, 117693432110646.	0.6	5
349	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2022, , .	1.5	12
350	Cyclosporine A Inhibits Viral Infection and Release as Well as Cytokine Production in Lung Cells by Three SARS-CoV-2 Variants. <i>Microbiology Spectrum</i> , 2022, 10, e0150421.	1.2	17

#	ARTICLE	IF	CITATIONS
351	Isolation and characterization of SARS-CoV-2 Beta variant from UAE travelers. <i>Journal of Infection and Public Health</i> , 2022, 15, 182-186.	1.9	22
352	Incidence Evaluation of SARS-CoV-2 Variants in the Ulsan Area, Korea, Using PowerChek SARS-CoV-2 S-gene Mutation Detection Kit: A Pilot Study. <i>Annals of Laboratory Medicine</i> , 2022, 42, 363-366.	1.2	2
353	SARS-CoV-2 mRNA Vaccine Breakthrough Infections in Fully Vaccinated Healthcare Personnel: A Systematic Review. <i>Tropical Medicine and Infectious Disease</i> , 2022, 7, 9.	0.9	14
354	First Identification of the New Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant (B.1.1.529) in Italy. <i>Clinical Infectious Diseases</i> , 2022, 75, 522-524.	2.9	17
355	Immune Response in Moderate to Critical Breakthrough COVID-19 Infection After mRNA Vaccination. <i>Frontiers in Immunology</i> , 2022, 13, 816220.	2.2	22
357	Comparative analyses of IgG/IgA neutralizing effects induced by three COVID-19 vaccines against variants of concern. <i>Journal of Allergy and Clinical Immunology</i> , 2022, 149, 1242-1252.e12.	1.5	23
358	Immunology and Technology of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccines. <i>Pharmacological Reviews</i> , 2022, 74, 313-339.	7.1	9
360	The ins and outs of SARS-CoV-2 variants of concern (VOCs). <i>Archives of Virology</i> , 2022, 167, 327-344.	0.9	35
361	SARS-CoV-2 Variants, Vaccines, and Host Immunity. <i>Frontiers in Immunology</i> , 2021, 12, 809244.	2.2	176
362	SARS-CoV-2 Nucleocapsid Protein TR-FRET Assay Amenable to High Throughput Screening. <i>ACS Pharmacology and Translational Science</i> , 2022, 5, 8-19.	2.5	5
363	Multiplexed Lab-on-a-Chip Bioassays for Testing Antibodies against SARS-CoV-2 and Its Variants in Multiple Individuals. <i>Analytical Chemistry</i> , 2022, 94, 2510-2516.	3.2	7
364	Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants. <i>Vaccines</i> , 2022, 10, 72.	2.1	13
365	The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines. <i>Frontiers in Medicine</i> , 2021, 8, 806641.	1.2	22
366	Antidepressant and Antipsychotic Drugs Reduce Viral Infection by SARS-CoV-2 and Fluoxetine Shows Antiviral Activity Against the Novel Variants in vitro. <i>Frontiers in Pharmacology</i> , 2021, 12, 755600.	1.6	34
369	The Effectiveness of COVID-19 Vaccines in Improving the Outcomes of Hospitalized COVID-19 Patients. <i>Cureus</i> , 2022, 14, e21485.	0.2	10
370	Regional and temporal coordinated mutation patterns in SARS-CoV-2 spike protein revealed by a clustering and network analysis. <i>Scientific Reports</i> , 2022, 12, 1128.	1.6	28
371	Evaluation of the Gam-COVID-Vac and vaccine-induced neutralizing response against SARS-CoV-2 lineage P.1 variant in an Argentinean cohort. <i>Vaccine</i> , 2022, 40, 811-818.	1.7	9
372	Distinct mutations and lineages of SARS-CoV-2 virus in the early phase of COVID-19 pandemic and subsequent 1-year global expansion. <i>Journal of Medical Virology</i> , 2022, 94, 2035-2049.	2.5	7



#	ARTICLE	IF	CITATIONS
373	In vitro neutralizing activity of BNT162b2 mRNA-induced antibodies against full B.1.351 SARS-CoV-2 variant. <i>Transboundary and Emerging Diseases</i> , 2022, 69, 2649-2655.	1.3	1
374	Immune dynamics of SARS-CoV-2 virus evolution. <i>International Journal of Molecular and Immunology</i> , 0, 7, 3-15.	0.0	2
375	Limited spread of a rare spike E484K-harboring SARS-CoV-2 in Marseille, France. <i>Archives of Virology</i> , 2022, 167, 583.	0.9	3
376	COVID-19 reinfections among naturally infected and vaccinated individuals. <i>Scientific Reports</i> , 2022, 12, 1438.	1.6	79
378	Analisis Efikasi dan Efektivitas Vaksin COVID-19 terhadap Varian SARS-CoV-2: Sebuah Tinjauan Literatur. <i>Jurnal Kedokteran Meditek</i> , 2022, 28, 107-119.	0.1	0
379	Strategies for fighting pandemic virus infections: Integration of virology and drug delivery. <i>Journal of Controlled Release</i> , 2022, 343, 361-378.	4.8	11
380	Immune response to SARS-CoV-2 variants: A focus on severity, susceptibility, and preexisting immunity. <i>Journal of Infection and Public Health</i> , 2022, 15, 277-288.	1.9	21
381	Emergence of a recurrent insertion in the N-terminal domain of the SARS-CoV-2 spike glycoprotein. <i>Virus Research</i> , 2022, 310, 198674.	1.1	24
382	Multiple expansions of globally uncommon SARS-CoV-2 lineages in Nigeria. <i>Nature Communications</i> , 2022, 13, 688.	5.8	23
383	Characterization of Two Heterogeneous Lethal Mouse-Adapted SARS-CoV-2 Variants Recapitulating Representative Aspects of Human COVID-19. <i>Frontiers in Immunology</i> , 2022, 13, 821664.	2.2	22
384	Neutralization against Omicron SARS-CoV-2 from previous non-Omicron infection. <i>Nature Communications</i> , 2022, 13, 852.	5.8	92
385	A comprehensive review of SARS-CoV-2 vaccines: Pfizer, Moderna & Johnson & Johnson. <i>Human Vaccines and Immunotherapeutics</i> , 2022, 18, 1-12.	1.4	94
386	SARS-CoV-2 Variants and Vaccination. <i>Zoonoses</i> , 2022, 2, .	0.5	16
387	Analysis of COVID-19 Risk Following a Ring Vaccination Intervention to Address SARS-CoV-2 Alpha Variant Transmission in Montreal, Canada. <i>JAMA Network Open</i> , 2022, 5, e2147042.	2.8	2
388	A SARS-CoV-2 variant elicits an antibody response with a shifted immunodominance hierarchy. <i>PLoS Pathogens</i> , 2022, 18, e1010248.	2.1	48
389	Steep Decline in Binding Capability of SARS-CoV-2 Omicron Variant (B.1.1.529) RBD to the Antibodies in Early COVID-19 Convalescent Sera and Inactivated Vaccine Sera. <i>Viruses</i> , 2022, 14, 335.	1.5	12
390	Rapid characterization of spike variants via mammalian cell surface display. <i>Molecular Cell</i> , 2021, 81, 5099-5111.e8.	4.5	32
391	A rapid and affordable point of care test for antibodies against SARS-CoV-2 based on hemagglutination and artificial intelligence interpretation. <i>Scientific Reports</i> , 2021, 11, 24507.	1.6	7

#	ARTICLE	IF	CITATIONS
392	Deep dissection of the antiviral immune profile of patients with COVID-19. <i>Communications Biology</i> , 2021, 4, 1389.	2.0	9
393	SARS-CoV-2 spreads through cell-to-cell transmission. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2022, 119, .	3.3	145
396	Omicron SARS-CoV-2 Variant Spike Protein Shows an Increased Affinity to the Human ACE2 Receptor: An In Silico Analysis. <i>Pathogens</i> , 2022, 11, 45.	1.2	44
397	Hyperglycosylated spike of SARS-CoV-2 gamma variant induces breast cancer metastasis. <i>American Journal of Cancer Research</i> , 2021, 11, 4994-5005.	1.4	0
398	Clinical characteristics of COVID-19 patients in Xiaogan, China: comparison between recent imported cases and earlier local cases. <i>American Journal of Translational Research (discontinued)</i> , 2021, 13, 11999-12005.	0.0	0
399	Vaccine efficacy in mutant SARS-CoV-2 variants. , 2021, 4, 1-12.		4
400	Microfluidic point-of-care device for detection of early strains and B.1.1.7 variant of SARS-CoV-2 virus. <i>Lab on A Chip</i> , 2022, 22, 1297-1309.	3.1	25
401	Inhibitor screening using microarray identifies the high capacity of neutralizing antibodies to Spike variants in SARS-CoV-2 infection and vaccination. <i>Theranostics</i> , 2022, 12, 2519-2534.	4.6	3
403	The guiding principles for populational COVID-19 vaccine selection: A normative analysis through comparison of the strategies in Hong Kong and Singapore. <i>Journal of Global Health</i> , 2022, 12, 03004.	1.2	2
406	SARS-CoV-2 and Coronavirus Disease Mitigation: Treatment Options, Vaccinations and Variants. <i>Pathogens</i> , 2022, 11, 275.	1.2	9
407	mRNA vaccine-induced antibodies more effective than natural immunity in neutralizing SARS-CoV-2 and its high affinity variants. <i>Scientific Reports</i> , 2022, 12, 2628.	1.6	34
408	Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2. <i>Cell Host and Microbe</i> , 2022, 30, 485-488.e3.	5.1	80
410	Three doses of prototypic SARS-CoV-2 inactivated vaccine induce cross-protection against its variants of concern. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 61.	7.1	12
412	SARS-CoV-2 Mutations and Their Impact on Diagnostics, Therapeutics and Vaccines. <i>Frontiers in Medicine</i> , 2022, 9, 815389.	1.2	96
413	Molecular variants of SARS-CoV-2: antigenic properties and current vaccine efficacy. <i>Medical Microbiology and Immunology</i> , 2022, 211, 79-103.	2.6	9
414	Structural Dynamics and Molecular Evolution of the SARS-CoV-2 Spike Protein. <i>MBio</i> , 2022, 13, e0203021.	1.8	10
416	Computation of Antigenicity Predicts SARS-CoV-2 Vaccine Breakthrough Variants. <i>Frontiers in Immunology</i> , 2022, 13, 861050.	2.2	8
417	Defining the risk of SARS-CoV-2 variants on immune protection. <i>Nature</i> , 2022, 605, 640-652.	13.7	117

#	ARTICLE	IF	CITATIONS
419	Natural SARS-CoV-2 Infection Affects Neutralizing Activity in Saliva of Vaccinees. <i>Frontiers in Immunology</i> , 2022, 13, 820250.	2.2	20
420	The Impact of Evolving SARS-CoV-2 Mutations and Variants on COVID-19 Vaccines. <i>MBio</i> , 2022, 13, e0297921.	1.8	117
421	Mutations in the genome of severe acute respiratory syndrome coronavirus 2: implications for COVID-19 severity and progression. <i>Journal of International Medical Research</i> , 2022, 50, 030006052210864.	0.4	5
422	Neutralization of SARS-CoV-2 Variants by mRNA and Adenoviral Vector Vaccine-Elicited Antibodies. <i>Frontiers in Immunology</i> , 2022, 13, 797589.	2.2	30
423	A Comprehensive Investigation Regarding the Differentiation of the Procurable COVID-19 Vaccines. <i>AAPS PharmSciTech</i> , 2022, 23, 95.	1.5	3
424	Neutralizing antibodies against SARS-CoV-2 variants of concern elicited by the comirnaty COVID-19 vaccine in nursing home residents. <i>Scientific Reports</i> , 2022, 12, 3788.	1.6	22
425	Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds. <i>Frontiers in Immunology</i> , 2022, 13, 773982.	2.2	10
426	The ChAdOx1 vectored vaccine, AZD2816, induces strong immunogenicity against SARS-CoV-2 beta (B.1.351) and other variants of concern in preclinical studies. <i>EBioMedicine</i> , 2022, 77, 103902.	2.7	23
427	Nucleic Acid-Based COVID-19 Therapy Targeting Cytokine Storms: Strategies to Quell the Storm. <i>Journal of Personalized Medicine</i> , 2022, 12, 386.	1.1	5
428	Spike protein of SARS-CoV-2 variants: a brief review and practical implications. <i>Brazilian Journal of Microbiology</i> , 2022, 53, 1133-1157.	0.8	22
429	David versus goliath: ACE2-Fc receptor traps as potential SARS-CoV-2 inhibitors. <i>MAbs</i> , 2022, 14, 2057832.	2.6	7
430	BNT162b2-elicited neutralization of Delta plus, Lambda, Mu, B.1.1.519, and Theta SARS-CoV-2 variants. <i>Npj Vaccines</i> , 2022, 7, 41.	2.9	4
431	The spike glycoprotein of SARS-CoV-2: A review of how mutations of spike glycoproteins have driven the emergence of variants with high transmissibility and immune escape. <i>International Journal of Biological Macromolecules</i> , 2022, 208, 105-125.	3.6	41
432	Experimental veterinary SARS-CoV-2 vaccine cross neutralization of the Delta (B.1.617.2) variant virus in cats. <i>Veterinary Microbiology</i> , 2022, 268, 109395.	0.8	6
433	The non-pharmaceutical interventions may affect the advantage in transmission of mutated variants during epidemics: A conceptual model for COVID-19. <i>Journal of Theoretical Biology</i> , 2022, 542, 111105.	0.8	5
435	Discovery of Highly Potent Fusion Inhibitors with Potential Pan-Coronavirus Activity That Effectively Inhibit Major COVID-19 Variants of Concern (VOCs) in Pseudovirus-Based Assays. <i>Viruses</i> , 2022, 14, 69.	1.5	5
436	Development of an efficient Sanger sequencing-based assay for detecting SARS-CoV-2 spike mutations. <i>PLoS ONE</i> , 2021, 16, e0260850.	1.1	11
437	Analysis of Clinical Characteristics and Virus Strains Variation of Patients Infected With SARS-CoV-2 in Jiangsu Province—A Retrospective Study. <i>Frontiers in Public Health</i> , 2021, 9, 791600.	1.3	7

#	ARTICLE	IF	CITATIONS
438	Semi-Supervised Pipeline for Autonomous Annotation of SARS-CoV-2 Genomes. <i>Viruses</i> , 2021, 13, 2426.	1.5	5
439	Mutational landscape of SARS-CoV-2 genome in Turkey and impact of mutations on spike protein structure. <i>PLoS ONE</i> , 2021, 16, e0260438.	1.1	6
440	COVID-19 Vaccination: The Mainspring of Challenges and the Seed of Remonstrance. <i>Vaccines</i> , 2021, 9, 1474.	2.1	6
441	Advances in the design and development of SARS-CoV-2 vaccines. <i>Military Medical Research</i> , 2021, 8, 67.	1.9	26
442	Neutralization of SARS-CoV-2 Variants of Concern in Kidney Transplant Recipients after Standard COVID-19 Vaccination. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2022, 17, 98-106.	2.2	22
443	Intranasal administration of a single dose of a candidate live attenuated vaccine derived from an NSP16-deficient SARS-CoV-2 strain confers sterilizing immunity in animals. , 2022, 19, 588-601.		27
446	Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern: A Perspective for Emerging More Transmissible and Vaccine-Resistant Strains. <i>Viruses</i> , 2022, 14, 827.	1.5	14
447	Identification of Compounds With Antiviral Activity Against SARS-CoV-2 in the MMV Pathogen Box Using a Phenotypic High-Throughput Screening Assay. <i>Frontiers in Virology</i> , 2022, 2, .	0.7	6
448	Development of antibody resistance in emerging mutant strains of SARS CoVâ€2: Impediment for COVIDâ€19 vaccines. <i>Reviews in Medical Virology</i> , 2022, 32, e2346.	3.9	16
449	Functional Analysis of Spike from SARS-CoV-2 Variants Reveals the Role of Distinct Mutations in Neutralization Potential and Viral Infectivity. <i>Viruses</i> , 2022, 14, 803.	1.5	10
450	Omicron-included mutation-induced changes in epitopes of SARS-CoV-2 spike protein and effectiveness assessments of current antibodies. <i>Molecular Biomedicine</i> , 2022, 3, 12.	1.7	12
451	Risk factors for prolonged nucleic acid conversion time in patients with COVID-19.. <i>International Journal of Health Sciences</i> , 2022, 16, 32-36.	0.4	0
454	Pilot Investigation of SARS-CoV-2 Variants in the Island of Sicily Prior to and in the Second Wave of the COVID-19 Pandemic. <i>Frontiers in Microbiology</i> , 2022, 13, 869559.	1.5	2
455	SARS-CoV-2 Omicron Variant: Epidemiological Features, Biological Characteristics, and Clinical Significance. <i>Frontiers in Immunology</i> , 2022, 13, 877101.	2.2	74
456	LY-CoV1404 (bebtelovimab) potently neutralizes SARS-CoV-2 variants. <i>Cell Reports</i> , 2022, 39, 110812.	2.9	287
457	Peptide-Based Strategies Against SARS-CoV-2 Attack: An Updated In Silico Perspective. <i>Frontiers in Drug Discovery</i> , 2022, 2, .	1.1	6
458	Effect of cannabidiol on apoptosis and cellular interferon and interferon-stimulated gene responses to the SARS-CoV-2 genes ORF8, ORF10 and M protein. <i>Life Sciences</i> , 2022, 301, 120624.	2.0	7
459	COVID-19 Vaccines and the Efficacy of Currently Available Vaccines Against COVID-19 Variants. <i>Cureus</i> , 2022, , .	0.2	3

#	ARTICLE	IF	CITATIONS
460	Cumulative SARS-CoV-2 mutations and corresponding changes in immunity in an immunocompromised patient indicate viral evolution within the host. <i>Nature Communications</i> , 2022, 13, 2560.	5.8	64
461	COVID-19 vaccine development: milestones, lessons and prospects. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, 146.	7.1	153
462	nSARS-CoV-2 and COVID-19 Pandemic: From Emergence to Vaccination. <i>Dr Sulaiman Al Habib Medical Journal</i> , 0, , 1.	0.3	0
463	Characterization and antiviral susceptibility of SARS-CoV-2 Omicron BA.2. <i>Nature</i> , 2022, 607, 119-127.	13.7	174
464	Bioinformatics for the Origin and Evolution of Viruses. <i>Advances in Experimental Medicine and Biology</i> , 2022, 1368, 53-71.	0.8	2
465	Neutralization assays for SARS-CoV-2: Implications for assessment of protective efficacy of COVID-19 vaccines. <i>Indian Journal of Medical Research</i> , 2022, 155, 105.	0.4	2
466	Safety & effectiveness of COVID-19 vaccines: A narrative review. <i>Indian Journal of Medical Research</i> , 2022, 155, 91.	0.4	22
467	The Biological Functions and Clinical Significance of SARS-CoV-2 Variants of Concern. <i>Frontiers in Medicine</i> , 2022, 9, .	1.2	43
468	A conserved subunit vaccine designed against SARS-CoV-2 variants showed evidence in neutralizing the virus. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 4091-4114.	1.7	6
469	Probing structural basis for enhanced binding of SARS-CoV-2 P.1 variant spike protein with the human ACE2 receptor. <i>Journal of Cellular Biochemistry</i> , 2022, 123, 1207-1221.	1.2	3
470	Real-World Effectiveness of Global COVID-19 Vaccines Against SARS-CoV-2 Variants: A Systematic Review and Meta-Analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	25
471	Broad neutralization against SARS-CoV-2 variants induced by ancestral and B.1.351 AS03-Adjuvanted recombinant Plant-Derived Virus-Like particle vaccines. <i>Vaccine</i> , 2022, 40, 4017-4025.	1.7	7
472	Effects of Spike Mutations in SARS-CoV-2 Variants of Concern on Human or Animal ACE2-Mediated Virus Entry and Neutralization. <i>Microbiology Spectrum</i> , 2022, 10, .	1.2	24
474	Developing Pseudovirus-Based Neutralization Assay against Omicron-Included SARS-CoV-2 Variants. <i>Viruses</i> , 2022, 14, 1332.	1.5	12
475	Biological Properties of SARS-CoV-2 Variants: Epidemiological Impact and Clinical Consequences. <i>Vaccines</i> , 2022, 10, 919.	2.1	23
476	IgG Anti-Spike Antibodies and Surrogate Neutralizing Antibody Levels Decline Faster 3 to 10 Months After BNT162b2 Vaccination Than After SARS-CoV-2 Infection in Healthcare Workers. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	16
477	Neutralization of Omicron BA.1, BA.2, and BA.3 SARS-CoV-2 by 3 doses of BNT162b2 vaccine. <i>Nature Communications</i> , 2022, 13, .	5.8	63
478	mRNA delivery technologies: Toward clinical translation. <i>International Review of Cell and Molecular Biology</i> , 2022, , 207-293.	1.6	5

#	ARTICLE	IF	CITATIONS
479	Severe acute respiratory syndrome coronavirus-2: An era of struggle and discovery leading to the emergency use authorization of treatment and prevention measures based on computational analysis. , 2022, , 559-582.		0
481	Identification of SARS-CoV-2 Variants of Concern Using Amplicon Next-Generation Sequencing. Microbiology Spectrum, 2022, 10, .	1.2	10
482	mRNA vaccines: Past, present, future. Asian Journal of Pharmaceutical Sciences, 2022, 17, 491-522.	4.3	24
483	A Review on Immunological Responses to SARS-CoV-2 and Various COVID-19 Vaccine Regimens. Pharmaceutical Research, 2022, 39, 2119-2134.	1.7	10
484	Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Emerging Microbes and Infections, 2022, 11, 1828-1832.	3.0	32
485	Characterization of SARS-CoV-2 Spike mutations important for infection of mice and escape from human immune sera. Nature Communications, 2022, 13, .	5.8	19
486	Plasma and memory antibody responses to Gamma SARS-CoV-2 provide limited cross-protection to other variants. Journal of Experimental Medicine, 2022, 219, .	4.2	6
487	Clinical Performance of Rapid and Point-of-Care Antigen Tests for SARS-CoV-2 Variants of Concern: A Living Systematic Review and Meta-Analysis. Viruses, 2022, 14, 1479.	1.5	13
488	A novel hamster model of SARS-CoV-2 respiratory infection using a pseudotyped virus. Scientific Reports, 2022, 12, .	1.6	1
489	Characterization of SARS-CoV-2 Escape Mutants to a Pair of Neutralizing Antibodies Targeting the RBD and the NTD. International Journal of Molecular Sciences, 2022, 23, 8177.	1.8	5
490	SARS-CoV-2â€™s Variants of Concern: A Brief Characterization. Frontiers in Immunology, 0, 13, .	2.2	31
491	Peimine inhibits variants of <sc>SARSâ€CoV</sc> â€2 cell entry via blocking the interaction between viral spike protein and <sc>ACE2</sc>. Journal of Food Biochemistry, 2022, 46, .	1.2	8
492	Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern Italy. Frontiers in Microbiology, 0, 13, .	1.5	10
493	Tracking the turnover of SARS-CoV-2 VOCs Gamma to Delta in a Brazilian state (Minas Gerais) with a high-vaccination status. Virus Evolution, 2022, 8, .	2.2	10
494	Understanding the Excitation Wavelength Dependence and Thermal Stability of the SARS-CoV-2 Receptor-Binding Domain Using Surface-Enhanced Raman Scattering and Machine Learning. ACS Photonics, 2022, 9, 2963-2972.	3.2	10
495	Missense mutations in spike protein of SARSâ€CoVâ€2 delta variant contribute to the alteration in viral structure and interaction with hACE2 receptor. Immunity, Inflammation and Disease, 2022, 10, .	1.3	6
496	COVID-19 and vaccination: myths vs science. Expert Review of Vaccines, 2022, 21, 1603-1620.	2.0	23
497	Molecular dynamics and docking studies on potentially active natural phytochemicals for targeting SARS-CoV-2 main protease. Journal of Biomolecular Structure and Dynamics, 2023, 41, 6459-6475.	2.0	2

#	ARTICLE	IF	CITATIONS
498	Ongoing Mycophenolate Treatment Impairs Anti-SARS-CoV-2 Vaccination Response in Patients Affected by Chronic Inflammatory Autoimmune Diseases or Liver Transplantation Recipients: Results of the RIVALSA Prospective Cohort. <i>Viruses</i> , 2022, 14, 1766.	1.5	13
499	Severity of Illness Caused by Severe Acute Respiratory Syndrome Coronavirus 2 Variants of Concern in Children: A Single-Center Retrospective Cohort Study. <i>Journal of the Pediatric Infectious Diseases Society</i> , 2022, 11, 440-447.	0.6	15
500	STANDARD M10 SARS-CoV-2 Assay for Rapid Detection of SARS-CoV-2: Comparison of Four Real-Time PCR Assays. <i>Diagnostics</i> , 2022, 12, 1998.	1.3	4
501	Comparison of SARS-CoV-2 spike RNA sequences in feces and nasopharynx indicates intestinal replication. <i>Gut Pathogens</i> , 2022, 14, .	1.6	4
502	Monitoring of Both Humoral and Cellular Immunities Could Early Predict COVID-19 Vaccine Efficacy Against the Different SARS-CoV2 Variants. <i>Journal of Clinical Immunology</i> , 2023, 43, 31-45.	2.0	4
503	Neutralization activity of sera/IgG preparations from fully BNT162b2 vaccinated individuals against SARS-CoV-2 Alpha, Beta, Gamma, Delta, and Kappa variants. <i>Scientific Reports</i> , 2022, 12, .	1.6	9
504	ChAdOx1 nCoV-19 (AZD1222) or nCoV-19-Beta (AZD2816) protect Syrian hamsters against Beta Delta and Omicron variants. <i>Nature Communications</i> , 2022, 13, .	5.8	23
505	Fatality assessment and variant risk monitoring for COVID-19 using three new hospital occupancy related metrics. <i>EBioMedicine</i> , 2022, 83, 104225.	2.7	2
506	Unique mutations in SARS-CoV-2 Omicron subvariants' non-spike proteins: Potential impacts on viral pathogenesis and host immune evasion. <i>Microbial Pathogenesis</i> , 2022, 170, 105699.	1.3	37
507	SARS-CoV-2 Variants: Impact of Spike Mutations on Vaccine and Therapeutic Strategies. , 2022, , 143-160.		0
508	Knowledge of SARS-CoV-2 Epitopes and Population HLA Types Is Important in the Design of COVID-19 Vaccines. <i>Vaccines</i> , 2022, 10, 1606.	2.1	4
509	A study protocol for a double-blind randomised placebo-controlled trial evaluating the efficacy of carrageenan nasal and throat spray for COVID-19 prophylaxisâ€”ICE-COVID. <i>Trials</i> , 2022, 23, .	0.7	4
510	Frontline workers: Mediators of mucosal immunity in community acquired pneumonia and COVID-19. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	0
511	SARS-CoV-2 Variants, Current Vaccines and Therapeutic Implications for COVID-19. <i>Vaccines</i> , 2022, 10, 1538.	2.1	12
512	Quantifying Mutational Response to Track the Evolution of SARS-CoV-2 Spike Variants: Introducing a Statistical-Mechanics-Guided Machine Learning Method. <i>Journal of Physical Chemistry B</i> , 2022, 126, 7895-7905.	1.2	5
513	Dual spike and nucleocapsid mRNA vaccination confer protection against SARS-CoV-2 Omicron and Delta variants in preclinical models. <i>Science Translational Medicine</i> , 2022, 14, .	5.8	55
514	Improved Neutralisation of the SARS-CoV-2 Omicron Variant following a Booster Dose of Pfizer-BioNTech (BNT162b2) COVID-19 Vaccine. <i>Viruses</i> , 2022, 14, 2023.	1.5	8
515	Key mutations on spike protein altering ACE2 receptor utilization and potentially expanding host range of emerging SARSâ€œCoVâ€œ variants. <i>Journal of Medical Virology</i> , 2023, 95, .	2.5	11

#	ARTICLE	IF	CITATIONS
516	Differential patterns of cross-reactive antibody response against SARS-CoV-2 spike protein detected for chronically ill and healthy COVID-19 naïve individuals. <i>Scientific Reports</i> , 2022, 12, .	1.6	8
517	Mutations in SARS-CoV-2: Insights on structure, variants, vaccines, and biomedical interventions. <i>Biomedicine and Pharmacotherapy</i> , 2023, 157, 113977.	2.5	66
518	Molecular dynamics simulations of the spike trimeric ectodomain of the SARS-CoV-2 Omicron variant: structural relationships with infectivity, evasion to immune system and transmissibility. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 9326-9343.	2.0	4
519	ViMRT: a text-mining tool and search engine for automated virus mutation recognition. <i>Bioinformatics</i> , 2023, 39, .	1.8	3
521	The Role of Host Cell Glycans on Virus Infectivity: The SARS-CoV-2 Case. <i>Advanced Science</i> , 2023, 10, .	5.6	4
522	Genomic analysis of SARS-CoV-2 variants of concern circulating in Hawaiï™ to facilitate public-health policies. <i>PLoS ONE</i> , 2022, 17, e0278287.	1.1	0
523	Broadly neutralizing and protective nanobodies against SARS-CoV-2 Omicron subvariants BA.1, BA.2, and BA.4/5 and diverse sarbecoviruses. <i>Nature Communications</i> , 2022, 13, .	5.8	17
524	A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75. <i>Cell Reports</i> , 2023, 42, 111903.	2.9	34
525	The Levels of Anti-SARS-CoV-2 Spike Protein IgG Antibodies Before and After the Third Dose of Vaccination Against COVID-19. <i>Journal of Inflammation Research</i> , 0, Volume 16, 145-160.	1.6	5
526	Cross-immunity against SARS-COV-2 variants of concern in naturally infected critically ill COVID-19 patients. <i>Heliyon</i> , 2023, 9, e12704.	1.4	2
527	Intrinsic D614G and P681R/H mutations in SARS-CoV-2 VoCs Alpha, Delta, Omicron and viruses with D614G plus key signature mutations in spike protein alters fusogenicity and infectivity. <i>Medical Microbiology and Immunology</i> , 2023, 212, 103-122.	2.6	18
528	Universal access to vaccines in post-COVID bioeconomy: Redesign for variants of concern and patent protection. , 2023, , 37-76.		0
529	Tracking of Mutational Signature of SARS-CoV-2 Omicron on Distinct Continents and Little Difference was Found. <i>Viruses</i> , 2023, 15, 321.	1.5	0
530	Uptake of severe acute respiratory syndrome coronavirus 2 spike protein mediated by angiotensin converting enzyme 2 and ganglioside in human cerebrovascular cells. <i>Frontiers in Neuroscience</i> , 0, 17, .	1.4	2
531	Virus-like Particles of Nodavirus Displaying the Receptor Binding Domain of SARS-CoV-2 Spike Protein: A Potential VLP-Based COVID-19 Vaccine. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4398.	1.8	0
532	Outbreak.info genomic reports: scalable and dynamic surveillance of SARS-CoV-2 variants and mutations. <i>Nature Methods</i> , 2023, 20, 512-522.	9.0	111
533	An update on SARS-CoV-2 immunization and future directions. <i>Frontiers in Pharmacology</i> , 0, 14, .	1.6	2
534	Research progress in spike mutations of SARS-CoV-2 variants and vaccine development. <i>Medicinal Research Reviews</i> , 2023, 43, 932-971.	5.0	7



#	ARTICLE	IF	CITATIONS
535	Identifying promising druggable binding sites and their flexibility to target the receptor-binding domain of SARS-CoV-2 spike protein. <i>Computational and Structural Biotechnology Journal</i> , 2023, 21, 2339-2351.	1.9	5
536	Understanding Mutations in Human SARS-CoV-2 Spike Glycoprotein: A Systematic Review & Meta-Analysis. <i>Viruses</i> , 2023, 15, 856.	1.5	10
537	Fc-mediated pan-sarbecovirus protection after alphavirus vector vaccination. <i>Cell Reports</i> , 2023, 42, 112326.	2.9	13
538	Comprehensive deep mutational scanning reveals the pH induced stability and binding differences between SARS-CoV-2 spike RBD and human ACE2. <i>Journal of Biomolecular Structure and Dynamics</i> , 2023, 41, 15207-15218.	2.0	1
539	SARS-CoV-2: Structure, Pathogenesis, and Diagnosis. , 2024, , 24-51.		0
548	The Environmental Impacts of Natural Resources Depletion. <i>Lecture Notes in Civil Engineering</i> , 2023, , 705-714.	0.3	0